Table 1 Immunotherapies for NPC treatment
Target | Effects | Treatment | NCT number |
|---|---|---|---|
PD-1 | Bypass immune checkpoint | Nivolumab, Pembrolizumab, Toripalimab, Penpulimab, Camrelizumab, Sintilimab, Tislelizumab, Treprilimab, SHR-1701 | NCT02054806 [7], NCT02339558 [40], NCT02915432 [116], NCT03581786 [6], NCT03558191, NCT03267498, NCT03544099, NCT03734809, NCT03707509, NCT03925090, NCT03924986, NCT04282070, NCT04376866, NCT04447612, NCT04421469, NCT04534855, NCT04736810, NCT04833257, NCT04917770, NCT04944914, NCT04978012, NCT3707509, NCT05020925, NCT05097209, NCT05341193 |
PD-L1 | Bypass immune checkpoint | SHR-1701, Avelumab | NCT04282070, NCT05020925, NCT04562441 |
CTLA-4 & PD-1 | Bypass immune checkpoint | Ipilimumab, AK104, IBI310 | NCT03097939, NCT04220307, NCT04945421 |
LMP2 | Direct cytotoxicity | LMP2 Antigen-specific TCR T cell | NCT03925896 |
EBV | Direct cytotoxicity | Autologous EBV specific Cytotoxic T cell | NCT03648697, NCT02287311, NCT02578641 [117] |
TGF-β | Direct cytotoxicity | TGF-β Resistant CTLs | NCT02065362 |